Pharmaceutical analysis for a patient with rebamipide-induced Stevens-Johnson syndrome by clinical pharmacists

GONG Wenjun; ZOU Jian; XU Han; BIAN Yuan

doi:10.6039/j.issn.1001-0408.2023.10.21

您当前的位置：

首页 >

文章列表页 >

Pharmaceutical analysis for a patient with rebamipide-induced Stevens-Johnson syndrome by clinical pharmacists

更新时间：2025-09-27

- Pharmaceutical analysis for a patient with rebamipide-induced Stevens-Johnson syndrome by clinical pharmacists
- ZHONGGUO YAOFANG Vol. 34, Issue 10, Pages: 1262-1265(2023)
- 作者机构：
  
  1.彭州市人民医院临床药学科，四川彭州　611930
  2.西南医科大学附属自贡医院临床药学科，四川自贡　643020
  3.四川省医学科学院·四川省人民医院/电子科技大学附属医院药学部个体化药物治疗四川省重点实验室，成都　610072
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.10.21
  CLC： R969.3
- Received：28 November 2022，
  
  Revised：2023-04-20，
  
  Accepted：26 April 2023，
  
  Published：30 May 2023
- 稿件说明：
移动端阅览
龚文俊,邹剑,徐翰,等.临床药师对1例瑞巴派特致Stevens-Johnson综合征的药学分析[J].中国药房,2023,34(10):1262-1265.

GONG Wenjun,ZOU Jian,XU Han,et al.Pharmaceutical analysis for a patient with rebamipide-induced Stevens-Johnson syndrome by clinical pharmacists[J].ZHONGGUO YAOFANG,2023,34(10):1262-1265.
龚文俊,邹剑,徐翰,等.临床药师对1例瑞巴派特致Stevens-Johnson综合征的药学分析[J].中国药房,2023,34(10):1262-1265. DOI： 10.6039/j.issn.1001-0408.2023.10.21.

GONG Wenjun,ZOU Jian,XU Han,et al.Pharmaceutical analysis for a patient with rebamipide-induced Stevens-Johnson syndrome by clinical pharmacists[J].ZHONGGUO YAOFANG,2023,34(10):1262-1265. DOI： 10.6039/j.issn.1001-0408.2023.10.21.

摘要

目的

为瑞巴派特致Stevens-Johnson综合征的诊治提供参考，并探讨患者发生Stevens-Johnson综合征的易感因素。

方法

临床药师整理分析1例胃肠疾病患者的治疗过程，评价该患者所用药物与不良反应的关联性，以判断引起Stevens-Johnson综合征的可疑致敏药物；同时探讨患者发生Stevens-Johnson综合征的易感因素

结果与结论

引起该患者发生Stevens-Johnson综合征的可疑致敏药物包括艾普拉唑肠溶片、瑞巴派特片、康复新液。根据国家药品不良反应监测中心因果关系评价方法、诺氏评估量表、表皮坏死松解症的药物因果关系算法（ALDEN）评分标准，综合判断引起Stevens-Johnson综合征的可疑致敏药物为瑞巴派特。低蛋白状态、药物之间竞争性结合血浆蛋白、高龄、细菌合并病毒感染可能是该患者发生Stevens-Johnson综合征的易感因素。因此临床在使用瑞巴派特前，应详细询问患者过敏史，在使用过程中应加强对患者的用药监护，警惕严重的不良反应的发生，如发现异常应立即停药并及时给予对症处理，以保障患者用药的安全性和有效性。

Abstract

OBJECTIVE

To provide reference for the diagnosis and treatment of Stevens-Johnson syndrome caused by rebamipide， and to explore the predisposing factors of Stevens-Johnson syndrome.

METHODS

Clinical pharmacists analyzed the treatment process of a patient with gastrointestinal diseases and evaluated the correlation between the drug used and adverse reactions， in order to determine the suspected allergenic drug causing Stevens-Johnson syndrome. The predisposing factors of patients with Stevens-Johnson syndrome were explored.

RESULTS & CONCLUSIONS

The suspected allergenic drugs that caused the patient to develop Stevens-Johnson syndrome included Ilaprazole enteric-coated tablets， Rebamipide tablets and Kangfuxin liquid. In summary， the suspect drug was identified as Rebamipide tablets according to the causality evaluation method of the National Center for Adverse Drug Reaction Monitoring， Naranjo’s scoring method and the algorithm of drug causality for epidermal necrolysis scoring criteria. Hypoproteinemia， competitive binding of plasma proteins between drugs， advanced age， bacterial and viral infections were the predisposing factors of Stevens-Johnson syndrome. Therefore， before using rebamipide in clinical practice， it is necessary to inquire about the patient’s allergy history in detail. During the use process， it is necessary to strengthen the patient’s medication monitoring and be alert to the occurrence of serious adverse reactions. If any abnormalities are found， the medication should be stopped immediately and symptomatic treatment should be given as soon as possible to ensure the safety and effectiveness of the patient’s medication.

关键词

Keywords

references

SIMANENKOV V I ， TIKHONOV S V . Rebamipide：new opportunities of gastroenteroprotection [J ] . Ter Arkh ， 2015 ， 87 （ 12 ）： 134 - 137 .

中华医学会皮肤性病学分会药物不良反应研究中心 . Stevens-Johnson综合征/中毒性表皮坏死松解症诊疗专家共识 [J ] . 中华皮肤科杂志， 2021 ， 54 （ 5 ）： 376 - 381 .

CREAMER D ， WALSH S A ， DZIEWULSKI P ， et al . U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016 [J ] . Br J Dermatol ， 2016 ， 174 （ 6 ）： 1194 - 1227 .

BASTUJI-GARIN S ， FOUCHARD N ， BERTOCCHI M ， et al . SCORTEN：a severity-of-illness score for toxic epidermal necrolysis [J ] . J Invest Dermatol ， 2000 ， 115 （ 2 ）： 149 - 153 .

DIPHOORN J ， CAZZANIGA S ， GAMBA C ， et al . Incidence，causative factors and mortality rates of Stevens-Johnson syndrome（SJS）and toxic epidermal necrolysis（TEN）in northern Italy：data from the REACT registry [J ] . Pharmacoepidemiol Drug Saf ， 2016 ， 25 （ 2 ）： 196 - 203 .

闫成，蔡长春，薛洪源 . 醋甲唑胺致Stevens-Johnson综合征及中毒性表皮坏死溶解症文献分析 [J ] . 医药导报， 2013 ， 32 （ 2 ）： 269 - 272 .

NARANJO C A ， BUSTO U ， SELLERS E M ， et al . A method for estimating the probability of adverse drug re-actions [J ] . Clin Pharmacol Ther ， 1981 ， 30 （ 2 ）： 239 - 245 .

SASSOLAS B ， HADDAD C ， MOCKENHAUPT M ， et al . ALDEN，an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis：comparison with case-control analysis [J ] . Clin Pharmacol Ther ， 2010 ， 88 （ 1 ）： 60 - 68 .

MOCKENHAUPT M ， VIBOUD C ， DUNANT A ， et al . Stevens-Johnson syndrome and toxic epidermal necrolysis：assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study [J ] . J Invest Dermatol ， 2008 ， 128 （ 1 ）： 35 - 44 .

赵辨 . 中国临床皮肤病学 [M ] . 2版 . 南京：江苏凤凰科学技术出版社， 2017 ： 479 .

MONASTIRLI A ， PASMATZI E ， BADAVANIS G ， et al . Erythema multiforme following pneumococcal vaccination [J ] . Acta Dermatovenerol Alp Pannonica Adriat ， 2017 ， 26 （ 1 ）： 25 - 26 .

夏倩倩，孙勇虎 . Stevens-Johnson综合征/中毒性表皮坏死松解综合征的发病机制研究进展 [J ] . 中国皮肤性病学杂志， 2019 ， 33 （ 6 ）： 713 - 716 .

中华预防医学会过敏病预防与控制专业委员会预防食物药物过敏学组 . 药物过敏诊断和预防方案中国专家共识 [J ] . 中华预防医学杂志， 2022 ， 56 （ 6 ）： 682 - 706 .

Views

184

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmaceutical monitoring and analysis of a case of severe systemic allergic reaction caused by Wujia shenghua capsules during the postpartum period

Mining and analysis of adverse drug event signals related to mepolizumab

Mining and analysis of risperidone adverse event signals based on FAERS database

我院1 557 例药品不良反应报告分析

我院1557例药品不良反应报告分析

Related Author

ZHAO Mingming

YE Yiqing

WU Shaoxing

LI Haoxuan

CHEN Yaoxin

XU Yinji

HUANG Ling

WANG Fengling

Related Institution

Dept. of Pharmacy， Jilin Branch， Women’s Hospital， Zhejiang University School of Medicine

Dept. of Pharmacy， Women’s Hospital， Zhejiang University School of Medicine

The Second Clinical Medical College， Guangzhou University of Chinese Medicine

Dept. of Respiratory and Critical Care Medicine， Guangdong Provincial Hospital of Traditional Chinese Medicine

Dept. of Pharmacy，the First Affiliated Hospital of Chengdu Medical College

⁰